Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
- PMID: 35256934
- PMCID: PMC8897153
- DOI: 10.1016/j.apsb.2021.09.019
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat HCC, such as targeted tyrosine kinase inhibitors, immune based therapies and combination of chemotherapy. However, limitations exist in current strategies including chemoresistance for instance. Tumor initiation and progression is driven by reprogramming of metabolism, in particular during HCC development. Recently, metabolic associated fatty liver disease (MAFLD), a reappraisal of new nomenclature for non-alcoholic fatty liver disease (NAFLD), indicates growing appreciation of metabolism in the pathogenesis of liver disease, including HCC, thereby suggesting new strategies by targeting abnormal metabolism for HCC treatment. In this review, we introduce directions by highlighting the metabolic targets in glucose, fatty acid, amino acid and glutamine metabolism, which are suitable for HCC pharmaceutical intervention. We also summarize and discuss current pharmaceutical agents and studies targeting deregulated metabolism during HCC treatment. Furthermore, opportunities and challenges in the discovery and development of HCC therapy targeting metabolism are discussed.
Keywords: 1,3-BPG, 1,3-bisphosphoglycerate; 2-DG, 2-deoxy-d-glucose; 3-BrPA, 3-bromopyruvic acid; ACC, acetyl-CoA carboxylase; ACLY, adenosine triphosphate (ATP) citrate lyase; ACS, acyl-CoA synthease; AKT, protein kinase B; AML, acute myeloblastic leukemia; AMPK, adenosine mono-phosphate-activated protein kinase; ASS1, argininosuccinate synthase 1; ATGL, adipose triacylglycerol lipase; CANA, canagliflozin; CPT, carnitine palmitoyl-transferase; CYP4, cytochrome P450s (CYPs) 4 family; Cancer therapy; DNL, de novo lipogenesis; EMT, epithelial-to-mesenchymal transition; ER, endoplasmic reticulum; ERK, extracellular-signal regulated kinase; FABP1, fatty acid binding protein 1; FASN, fatty acid synthase; FBP1, fructose-1,6-bisphosphatase 1; FFA, free fatty acid; Fatty acid β-oxidation; G6PD, glucose-6-phosphate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLS1, renal-type glutaminase; GLS2, liver-type glutaminase; GLUT1, glucose transporter 1; GOT1, glutamate oxaloacetate transaminase 1; Glutamine metabolism; Glycolysis; HCC, hepatocellular carcinoma; HIF-1α, hypoxia-inducible factor-1 alpha; HK, hexokinase; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; HSCs, hepatic stellate cells; Hepatocellular carcinoma; IDH2, isocitrate dehydrogenase 2; LCAD, long-chain acyl-CoA dehydrogenase; LDH, lactate dehydrogenase; LPL, lipid lipase; LXR, liver X receptor; MAFLD, metabolic associated fatty liver disease; MAGL, monoacyglycerol lipase; MCAD, medium-chain acyl-CoA dehydrogenase; MEs, malic enzymes; MMP9, matrix metallopeptidase 9; Metabolic dysregulation; NADPH, nicotinamide adenine nucleotide phosphate; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OTC, ornithine transcarbamylase; PCK1, phosphoenolpyruvate carboxykinase 1; PFK1, phosphofructokinase 1; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PI3K, phosphoinositide 3-kinase; PKM2, pyruvate kinase M2; PPARα, peroxisome proliferator-activated receptor alpha; PPP, pentose phosphate pathway; Pentose phosphate pathway; ROS, reactive oxygen species; SCD1, stearoyl-CoA-desaturase 1; SGLT2, sodium-glucose cotransporter 2; SLC1A5/ASCT2, solute carrier family 1 member 5/alanine serine cysteine preferring transporter 2; SLC7A5/LAT1, solute carrier family 7 member 5/L-type amino acid transporter 1; SREBP1, sterol regulatory element-binding protein 1; TAGs, triacylglycerols; TCA cycle, tricarboxylic acid cycle; TKIs, tyrosine kinase inhibitors; TKT, transketolase; Tricarboxylic acid cycle; VEGFR, vascular endothelial growth factor receptor; WD-fed MC4R-KO, Western diet (WD)-fed melanocortin 4 receptor-deficient (MC4R-KO); WNT, wingless-type MMTV integration site family; mIDH, mutant IDH; mTOR, mammalian target of rapamycin.
© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Figures
![Image 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8897153/bin/ga1.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8897153/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8897153/bin/gr2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8897153/bin/gr3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8897153/bin/gr4.gif)
Similar articles
-
The ménage à trois of autophagy, lipid droplets and liver disease.Autophagy. 2022 Jan;18(1):50-72. doi: 10.1080/15548627.2021.1895658. Epub 2021 Apr 2. Autophagy. 2022. PMID: 33794741 Free PMC article. Review.
-
Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).Cell Mol Gastroenterol Hepatol. 2017 Dec 13;5(3):367-398. doi: 10.1016/j.jcmgh.2017.11.016. eCollection 2018 Mar. Cell Mol Gastroenterol Hepatol. 2017. PMID: 29552625 Free PMC article.
-
MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers.Comput Struct Biotechnol J. 2016 Jun 4;14:223-33. doi: 10.1016/j.csbj.2016.05.005. eCollection 2016. Comput Struct Biotechnol J. 2016. PMID: 27358718 Free PMC article. Review.
-
Regulation of energy metabolism by long-chain fatty acids.Prog Lipid Res. 2014 Jan;53:124-44. doi: 10.1016/j.plipres.2013.12.001. Epub 2013 Dec 18. Prog Lipid Res. 2014. PMID: 24362249 Review.
-
Free radical biology for medicine: learning from nonalcoholic fatty liver disease.Free Radic Biol Med. 2013 Dec;65:952-968. doi: 10.1016/j.freeradbiomed.2013.08.174. Epub 2013 Aug 29. Free Radic Biol Med. 2013. PMID: 23994574 Review.
Cited by
-
Role of lipid metabolism in hepatocellular carcinoma.Discov Oncol. 2024 Jun 4;15(1):206. doi: 10.1007/s12672-024-01069-y. Discov Oncol. 2024. PMID: 38833109 Free PMC article. Review.
-
HIF-1α Pathway Orchestration by LCN2: A Key Player in Hypoxia-Mediated Colitis Exacerbation.Inflammation. 2024 May 31. doi: 10.1007/s10753-024-01990-y. Online ahead of print. Inflammation. 2024. PMID: 38819583
-
Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates Metabolic Dysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1.Int J Mol Sci. 2024 May 7;25(10):5086. doi: 10.3390/ijms25105086. Int J Mol Sci. 2024. PMID: 38791126 Free PMC article.
-
Celastrol inhibits mouse B16-F10 melanoma cell survival by regulating the PI3K/AKT/mTOR signaling pathway and repressing HIF-1α expression.Discov Oncol. 2024 May 21;15(1):178. doi: 10.1007/s12672-024-01045-6. Discov Oncol. 2024. PMID: 38771435 Free PMC article.
-
SPG21, a potential oncogene targeted by miR-128-3p, amplifies HBx-induced carcinogenesis and chemoresistance via activation of TRPM7-mediated JNK pathway in hepatocellular carcinoma.Cell Oncol (Dordr). 2024 May 16. doi: 10.1007/s13402-024-00955-5. Online ahead of print. Cell Oncol (Dordr). 2024. PMID: 38753154
References
-
- Chen W., Zheng R., Baade P.D., Zhang S., Zeng H., Bray F., et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. - PubMed
-
- Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. - PubMed
-
- Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462. - PubMed
-
- Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154–2160. - PubMed
-
- Qin S., Bai Y., Lim H.Y., Thongprasert S., Chao Y., Fan J., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501–3508. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous